Table 3 Ratios of GSH/GSSG before and after treatments with BORT and its combinations with CB and OX in A2780, A2780 cisR and SKOV-3 ovarian cancer cell lines
From: Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models
| Â | A2780 | A2780cisR | SKOV-3 |
|---|---|---|---|
Control | 241.32 | 40.2 | 38.00 |
BORT | 31.3 | 14.7 | 42.56 |
CB + BORT (0/2 h) | 78.35 | 13.1 | 38.53 |
CB + BORT (2/0 h) | 50.27 | 13.8 | 35.70 |
OX + BORT (0/2 h) | 71.77 | 39.25 | 38.16 |
OX + BORT (2/0 h) | 69.97 | 33.31 | 43.74 |